Alzheimer’s Disease Therapeutics Market Share, Size, Forecast and Trends by 2020 - PowerPoint PPT Presentation

Loading...

PPT – Alzheimer’s Disease Therapeutics Market Share, Size, Forecast and Trends by 2020 PowerPoint presentation | free to download - id: 81bf50-ODJiY



Loading


The Adobe Flash plugin is needed to view this content

Get the plugin now

View by Category
About This Presentation
Title:

Alzheimer’s Disease Therapeutics Market Share, Size, Forecast and Trends by 2020

Description:

Download Sample Brochure of Report @ A detailed qualitative analysis of the factors responsible for driving and restraining growth of the MRI Systems Market and future opportunities are provided in the report. – PowerPoint PPT presentation

Number of Views:12

less

Write a Comment
User Comments (0)
Transcript and Presenter's Notes

Title: Alzheimer’s Disease Therapeutics Market Share, Size, Forecast and Trends by 2020


1
Alzheimers Disease Therapeutics in Major
Developed Markets to 2021 - Aging Population and
Improved Disease Understanding Increase Demand
for Disease Modifying Agents
Published on 04 February, 2016 Number of
pages 171 Single User Price 4995
2
Summary of the report Alzheimer's Disease (AD)
is an irreversible, progressive neurodegenerative
disease, characterized by cognitive impairment,
memory loss and functional decline. Symptoms
typically begin to first appear in patients in
their mid-sixties, with symptoms appearing in
varying stages. The pathological features of AD
comprise histopathological changes within the
brain. Mild Cognitive Impairment (MCI) is a
heterogeneous condition between normal cognition
and dementia, whereby cognitive changes in mental
abilities, such as memory or thinking, are
affected. Almost all cases of AD begin with MCI,
but it should be noted that not all patients with
MCI go on to develop AD. Although there is a
high degree of failure and uncertainty within the
RD of AD drugs, the number of drugs in the
pipeline is considerably high at 559. The
majority of the pipeline products are novel
drugs, with a total of seven repositioned and
five generic drugs. This shows advancement in the
progression of the different molecules being
developed as therapeutic agents within the AD
pipeline.
3
  • The AD market has a lack of therapeutic options.
  • Which classes of drug dominate the market?
  • What newly approved therapies have entered the
    market?
  • How do the leading marketed therapies compare
    clinically?
  • How will the new therapies be positioned in the
    treatment of AD?
  • How have selected late-stage pipeline therapies
    performed in clinical trials?
  • The pipeline contains a range of molecule types
    and molecular targets, including those that are
    well established in AD, and novel, first-in-class
    therapies.
  • Which molecular targets appear most frequently in
    the pipeline?
  • AD clinical trials have an overall attrition rate
    of 94.
  • What are the failure rates for individual Phases
    of clinical development?
  • How do AD clinical trial characteristics,
    including failure rate, duration, and size
    compare against respiratory and industry
    averages?
  • The AD market is forecast to rise from a value of
    5.2 billion in 2014 to 11.3 billion in 2021, at
    a CAGR of 11.8 across the eight major markets
    assessed.
  • How much of a role will disease prevalence and
    new product approvals play in market growth?
  • Will generic competition have a significant
    impact on the market over the forecast period?
  • There have been 170 licensing deals and 104
    co-development deals pertaining to AD products
    since 2006.
  • Which territories show the most deal activity?
  • What were the trends in deal completion by
    product stage of development?
  • What were the conditions of the key licensing or
    co-development deals to take place in AD?

Click Here To Check Complete Report
4
This report will allow you to Understand the
current clinical and commercial landscape through
a comprehensive study of disease pathogenesis,
diagnosis, prognosis, and the current treatment
algorithm used in AD. Assess the safety and
efficacy of current treatment options, with
extensive product profiles on prominent marketed
therapies, and a heatmap directly comparing
safety and efficacy data. Analyze the AD
pipeline and stratify by stage of development,
molecule type, and molecular target. The most
promising late-stage therapies are profiled and
assessed in terms of clinical performance and
competitiveness, alongside a single-product
forecast. Predict growth in market size in
eight major markets, with in-depth market
forecasting from 2014 to 2021. The forecasts will
provide an understanding of how epidemiology
trends, new drug entries, and patent expirations
will influence market value. Identify
commercial opportunities in the AD deals
landscape by analyzing trends in licensing and
co-development deals, and by profiling the most
significant deals that have occurred in this
indication in recent years.
Download Sample Brochure
5
Key questions answered in this report  What
will the market size be in 2020 and what will the
growth rate be? What are the key market
trends? What is driving this market? What are
the challenges to market growth? Who are the
key vendors in this market space? What are the
market opportunities and threats faced by the key
vendors? What are the strengths and weaknesses
of the key vendors? You can request one free
hour of our analysts time when you purchase this
market report. Details are provided within the
report.
Make an Inquiry Before Buying
6
Alzheimers Disease Therapeutics in Major
Developed Markets to 2021 - Aging Population and
Improved Disease Understanding Increase Demand
for Disease Modifying Agents
A detailed qualitative analysis of the factors
responsible for driving and restraining growth of
the Alzheimers Disease Therapeutics in Major
Developed Markets to 2021 and future
opportunities are provided in the report.
Contact 1-302-684-6088 sales_at_marketintelreports.c
om www.marketintelreports.com
Click here to order a copy of Alzheimers Disease
Therapeutics in Major Developed Markets to
2021Industry Report
About PowerShow.com